Personalize immunotherapy

Artificial Intelligence

In the next decade of personalized medicine in cancer and pathology, AI will play a pivotal role in translating “super-human” complex patterns into actionable insights. To achieve this, the recipe is clear: big data, big AI expertise all combined with in depth medical expertise. But what does “big” even mean? For instance, is it realistic to expect a pathologist to identify millions of cells in just a single gigantic H&E slide to train the AI algorithm, let alone repeat that for thousands of slides? This unrealistic level of “big data”, is the guidance today’s machine learning algorithms require. Under the leadership of expert pathologists and medical researchers at the world-class Netherlands Cancer Institute, and of expert professors of AI at the University of Amsterdam, Ellogon.AI has the answer. Our proprietary and groundbreaking Exclusive Deep Learning Technology does not just blindly copy the pathologist but extrapolates. By exploiting sparse-shot and self-supervised neural dynamics during the extremely high-dimensional optimization, Ellogon’s Exclusive Deep Learning recognizes millions of cells and “super-human” patterns in raw H&E and PD-L1 stained histopathology images; it quantifies immunogram biomarkers including Tumor Infiltrating Lymphocytes (TIL’s), PD-L1 inhibition checkpoints, and Tumor Mutation Burden (TMB); it delivers personalized response to immunotherapy of which the patient will benefit from treatment; validated thoroughly in multi-center medical data and cohors worldwide; quality assured to meet CE-certified standards of excellence and quality according to current regulation standards.